{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:24:12Z","timestamp":1786947852501,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01435-8","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:25:26Z","timestamp":1786944326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative bulk and single-cell transcriptomics identify a recurrence-prognostic risk model with exploratory associations with treatment-response phenotypes in colorectal cancer"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7239-1649","authenticated-orcid":false,"given":"Shuai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyue","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganggang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"3","key":"1435_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1435_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.5306\/wjco.v15.i9.1136","volume":"15","author":"H Fadlallah","year":"2024","unstructured":"Fadlallah H, El Masri J, Fakhereddine H, et al. Colorectal cancer: recent advances in management and treatment. World J Clin Oncol. 2024;15(9):1136\u201356. https:\/\/doi.org\/10.5306\/wjco.v15.i9.1136.","journal-title":"World J Clin Oncol"},{"issue":"17","key":"1435_CR3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731\u201340. https:\/\/doi.org\/10.1056\/NEJMoa040694.","journal-title":"N Engl J Med"},{"issue":"23","key":"1435_CR4","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343\u201351. https:\/\/doi.org\/10.1056\/NEJMoa032709.","journal-title":"N Engl J Med"},{"issue":"13","key":"1435_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343(13):905\u201314. https:\/\/doi.org\/10.1056\/NEJM200009283431302. (Irinotecan Study Group).","journal-title":"N Engl J Med"},{"issue":"23","key":"1435_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u201342. https:\/\/doi.org\/10.1056\/NEJMoa032691.","journal-title":"N Engl J Med"},{"issue":"23","key":"1435_CR7","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017;317(23):2392\u2013401. https:\/\/doi.org\/10.1001\/jama.2017.7105.","journal-title":"JAMA"},{"issue":"23","key":"1435_CR8","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"issue":"8","key":"1435_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13(8):1551\u201369. https:\/\/doi.org\/10.3390\/molecules13081551.","journal-title":"Molecules"},{"issue":"9","key":"1435_CR10","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1111\/cas.14532","volume":"111","author":"S Blondy","year":"2020","unstructured":"Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N. 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;111(9):3142\u201354. https:\/\/doi.org\/10.1111\/cas.14532.","journal-title":"Cancer Sci"},{"issue":"7","key":"1435_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"AB van Kuilenburg","year":"2004","unstructured":"van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2003.12.004.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1435_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.20517\/cdr.2022.136","volume":"6","author":"WH Gmeiner","year":"2023","unstructured":"Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023;6(2):257\u201372. https:\/\/doi.org\/10.20517\/cdr.2022.136.","journal-title":"Cancer Drug Resist"},{"key":"1435_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9390878","volume":"2020","author":"S Yuan","year":"2020","unstructured":"Yuan S, Tao F, Zhang X, Zhang Y, Sun X, Wu D. Role of Wnt\/\u03b2-catenin signaling in the chemoresistance modulation of colorectal cancer. BioMed Res Int. 2020;2020:9390878. https:\/\/doi.org\/10.1155\/2020\/9390878.","journal-title":"BioMed Res Int"},{"issue":"1","key":"1435_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cas.14253","volume":"111","author":"H Wang","year":"2020","unstructured":"Wang H, Li JM, Wei W, et al. Regulation of ATP-binding cassette subfamily B member 1 by Snail contributes to chemoresistance in colorectal cancer. Cancer Sci. 2020;111(1):84\u201397. https:\/\/doi.org\/10.1111\/cas.14253.","journal-title":"Cancer Sci"},{"issue":"37","key":"1435_CR15","doi-asserted-by":"publisher","first-page":"59766","DOI":"10.18632\/oncotarget.11121","volume":"7","author":"S Gon\u00e7alves-Ribeiro","year":"2016","unstructured":"Gon\u00e7alves-Ribeiro S, D\u00edaz-Maroto NG, Berdiel-Acer M, et al. Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells. Oncotarget. 2016;7(37):59766\u201380. https:\/\/doi.org\/10.18632\/oncotarget.11121.","journal-title":"Oncotarget"},{"issue":"1","key":"1435_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01864-z","volume":"40","author":"A Kumar","year":"2022","unstructured":"Kumar A, Singh AK, Singh H, Thareja S, Kumar P. Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. Med Oncol. 2022;40(1):3. https:\/\/doi.org\/10.1007\/s12032-022-01864-z.","journal-title":"Med Oncol"},{"issue":"11","key":"1435_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350\u20136. https:\/\/doi.org\/10.1038\/nm.3967.","journal-title":"Nat Med"},{"issue":"5","key":"1435_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"issue":"18","key":"1435_CR19","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka K, Hofree M, Chen JH, et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021;184(18):4734-4752.e20. https:\/\/doi.org\/10.1016\/j.cell.2021.08.003.","journal-title":"Cell"},{"issue":"7","key":"1435_CR20","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41588-022-01100-4","volume":"54","author":"I Joanito","year":"2022","unstructured":"Joanito I, Wirapati P, Zhao N, et al. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nat Genet. 2022;54(7):963\u201375. https:\/\/doi.org\/10.1038\/s41588-022-01100-4.","journal-title":"Nat Genet"},{"issue":"1","key":"1435_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02252-9","volume":"21","author":"H Zheng","year":"2021","unstructured":"Zheng H, Liu H, Ge Y, Wang X. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer. Cancer Cell Int. 2021;21(1):552. https:\/\/doi.org\/10.1186\/s12935-021-02252-9.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"1435_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782\u201395. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.003.","journal-title":"Immunity"},{"issue":"1","key":"1435_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"issue":"3","key":"1435_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","volume":"24","author":"C Tournigand","year":"2006","unstructured":"Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006;24(3):394\u2013400. https:\/\/doi.org\/10.1200\/JCO.2005.03.0106.","journal-title":"J Clin Oncol"},{"issue":"33","key":"1435_CR25","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1200\/JCO.22.02773","volume":"41","author":"A de Gramont","year":"2023","unstructured":"de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2023;41(33):5080\u20139. https:\/\/doi.org\/10.1200\/JCO.22.02773.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1435_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","volume":"16","author":"S Hegewisch-Becker","year":"2015","unstructured":"Hegewisch-Becker S, Graeven U, Lerchenm\u00fcller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015;16(13):1355\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(15)00042-X.","journal-title":"Lancet Oncol"},{"issue":"23","key":"1435_CR27","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1158\/0008-5472.CAN-21-1572","volume":"81","author":"M Malier","year":"2021","unstructured":"Malier M, Gharzeddine K, Laverriere MH, et al. Hypoxia drives dihydropyrimidine dehydrogenase expression in macrophages and confers chemoresistance in colorectal cancer. Cancer Res. 2021;81(23):5963\u201376. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1572.","journal-title":"Cancer Res"},{"issue":"1","key":"1435_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19173-2","volume":"11","author":"YH Cho","year":"2020","unstructured":"Cho YH, Ro EJ, Yoon JS, et al. 5-FU promotes stemness of colorectal cancer via p53-mediated WNT\/\u03b2-catenin pathway activation. Nat Commun. 2020;11(1):5321. https:\/\/doi.org\/10.1038\/s41467-020-19173-2.","journal-title":"Nat Commun"},{"issue":"2","key":"1435_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5487\/TR.2015.31.2.151","volume":"31","author":"AY Kim","year":"2015","unstructured":"Kim AY, Kwak JH, Je NK, Lee YH, Jung YS. Epithelial-mesenchymal transition is associated with acquired resistance to 5-fluorocuracil in HT-29 colon cancer cells. Toxicol Res. 2015;31(2):151\u20136. https:\/\/doi.org\/10.5487\/TR.2015.31.2.151.","journal-title":"Toxicol Res"},{"issue":"9","key":"1435_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/biology10090854","volume":"10","author":"S Azwar","year":"2021","unstructured":"Azwar S, Seow HF, Abdullah M, Faisal Jabar M, Mohtarrudin N. Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology (Basel). 2021;10(9):854. https:\/\/doi.org\/10.3390\/biology10090854.","journal-title":"Biology (Basel)"},{"key":"1435_CR31","doi-asserted-by":"publisher","first-page":"13137","DOI":"10.2147\/CMAR.S274447","volume":"12","author":"R Chen","year":"2020","unstructured":"Chen R, Zhou S, Chen J, Lin S, Ye F, Jiang P. LncRNA BLACAT1\/miR-519d-3p\/CREB1 axis mediates proliferation, apoptosis, migration, invasion, and drug-resistance in colorectal cancer progression. Cancer Manag Res. 2020;12:13137\u201348. https:\/\/doi.org\/10.2147\/CMAR.S274447.","journal-title":"Cancer Manag Res"},{"issue":"4","key":"1435_CR32","doi-asserted-by":"publisher","first-page":"8087","DOI":"10.1080\/21655979.2022.2047556","volume":"13","author":"D Li","year":"2022","unstructured":"Li D, Wang D, Liu H, Jiang X. LEM domain containing 1 (LEMD1) transcriptionally activated by SRY-related high-mobility-group box 4 (SOX4) accelerates the progression of colon cancer by upregulating phosphatidylinositol 3-kinase (PI3K)\/protein kinase B (Akt) signaling pathway. Bioengineered. 2022;13(4):8087\u2013100. https:\/\/doi.org\/10.1080\/21655979.2022.2047556.","journal-title":"Bioengineered"},{"issue":"11","key":"1435_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112924","volume":"15","author":"X Li","year":"2023","unstructured":"Li X, Jiang S, Jiang T, et al. LEM domain containing 1 acts as a novel oncogene and therapeutic target for triple-negative breast cancer. Cancers (Basel). 2023;15(11):2924. https:\/\/doi.org\/10.3390\/cancers15112924.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1435_CR34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.7150\/ijms.22823","volume":"15","author":"IW Chang","year":"2018","unstructured":"Chang IW, Liu KW, Ragunanan M, He HL, Shiue YL, Yu SC. SERPINB5 expression: association with CCRT response and prognostic value in rectal cancer. Int J Med Sci. 2018;15(4):376\u201384. https:\/\/doi.org\/10.7150\/ijms.22823.","journal-title":"Int J Med Sci"},{"issue":"11","key":"1435_CR35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i11.103412","volume":"31","author":"ZS Meng","year":"2025","unstructured":"Meng ZS, Hu JT, Wu H, Li BK. Inhibition of the SERPINB5\/HSP90AA1 axis restrains the proliferation and invasion of rectal cancer. World J Gastroenterol. 2025;31(11):103412. https:\/\/doi.org\/10.3748\/wjg.v31.i11.103412.","journal-title":"World J Gastroenterol"},{"issue":"56","key":"1435_CR36","doi-asserted-by":"publisher","first-page":"95256","DOI":"10.18632\/oncotarget.20438","volume":"8","author":"D Cano-Rodriguez","year":"2017","unstructured":"Cano-Rodriguez D, Campagnoli S, Grandi A, et al. TCTN2: a novel tumor marker with oncogenic properties. Oncotarget. 2017;8(56):95256\u201369. https:\/\/doi.org\/10.18632\/oncotarget.20438.","journal-title":"Oncotarget"},{"issue":"1","key":"1435_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11519-5","volume":"23","author":"L Jia","year":"2023","unstructured":"Jia L, Liao L, Jiang Y, et al. Low-dose adropin stimulates inflammasome activation of macrophage via mitochondrial ROS involved in colorectal cancer progression. BMC Cancer. 2023;23(1):1042. https:\/\/doi.org\/10.1186\/s12885-023-11519-5.","journal-title":"BMC Cancer"},{"key":"1435_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01480","volume":"9","author":"M Chiu","year":"2020","unstructured":"Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O. Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia. Front Oncol. 2020;9:1480. https:\/\/doi.org\/10.3389\/fonc.2019.01480.","journal-title":"Front Oncol"},{"issue":"3","key":"1435_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2015.1017688","volume":"3","author":"AS Gehren","year":"2015","unstructured":"Gehren AS, Rocha MR, de Souza WF, Morgado-D\u00edaz JA. Alterations of the apical junctional complex and actin cytoskeleton and their role in colorectal cancer progression. Tissue Barriers. 2015;3(3):e1017688. https:\/\/doi.org\/10.1080\/21688370.2015.1017688.","journal-title":"Tissue Barriers"},{"key":"1435_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.851401","volume":"13","author":"B Shi","year":"2022","unstructured":"Shi B, Xu FF, Xiang CP, Li CY, Fan P, Wang H. HIF1\u03b1\/VEGF feedback loop contributes to 5-fluorouracil resistance. Front Pharmacol. 2022;13:851401. https:\/\/doi.org\/10.3389\/fphar.2022.851401.","journal-title":"Front Pharmacol"},{"issue":"3","key":"1435_CR41","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/0008-5472.CAN-10-0714","volume":"71","author":"S Van Schaeybroeck","year":"2011","unstructured":"Van Schaeybroeck S, Kyula JN, Fenton A, et al. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res. 2011;71(3):1071\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0714.","journal-title":"Cancer Res"},{"key":"1435_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1572701","volume":"16","author":"J Pei","year":"2025","unstructured":"Pei J, Gao Y, Xing B, Chen Y, Wu A. Identification of a coagulation-related classification and signature that predict disease heterogeneity for colorectal cancer and pan-cancer patients. Front Immunol. 2025;16:1572701. https:\/\/doi.org\/10.3389\/fimmu.2025.1572701.","journal-title":"Front Immunol"},{"issue":"8","key":"1435_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0128-8","volume":"50","author":"L He","year":"2018","unstructured":"He L, Zhu H, Zhou S, et al. Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. Exp Mol Med. 2018;50(8):1\u201312. https:\/\/doi.org\/10.1038\/s12276-018-0128-8.","journal-title":"Exp Mol Med"},{"issue":"2","key":"1435_CR44","doi-asserted-by":"publisher","first-page":"622","DOI":"10.4143\/crt.2019.593","volume":"52","author":"G Zhang","year":"2020","unstructured":"Zhang G, Luo X, Zhang W, et al. CXCL-13 regulates resistance to 5-fluorouracil in colorectal cancer. Cancer Res Treat. 2020;52(2):622\u201333. https:\/\/doi.org\/10.4143\/crt.2019.593.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"1435_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27082","volume":"10","author":"QL Ou","year":"2024","unstructured":"Ou QL, Cheng L, Chang YL, Liu JH, Zhang SF. Jianpi Jiedu decoction reverses 5-fluorouracil resistance in colorectal cancer by suppressing the xCT\/GSH\/GPX4 axis to induce ferroptosis. Heliyon. 2024;10(5):e27082. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27082.","journal-title":"Heliyon"},{"key":"1435_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153895","volume":"234","author":"YL Qu","year":"2022","unstructured":"Qu YL, Liu XL, Zhao SY, Zhai XF. SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer. Pathol Res Pract. 2022;234:153895. https:\/\/doi.org\/10.1016\/j.prp.2022.153895.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"1435_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41467-021-27847-8","volume":"13","author":"G Therizols","year":"2022","unstructured":"Therizols G, Bash-Imam Z, Panthu B, et al. Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance. Nat Commun. 2022;13(1):173. https:\/\/doi.org\/10.1038\/s41467-021-27847-8.","journal-title":"Nat Commun"},{"issue":"2","key":"1435_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3892\/or.12.2.275","volume":"12","author":"D Yuki","year":"2004","unstructured":"Yuki D, Lin YM, Fujii Y, Nakamura Y, Furukawa Y. Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers. Oncol Rep. 2004;12(2):275\u201380. https:\/\/doi.org\/10.3892\/or.12.2.275.","journal-title":"Oncol Rep"},{"key":"1435_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.823696","volume":"12","author":"H Zhang","year":"2022","unstructured":"Zhang H, Xu C, Jiang F, Feng J. A three-genes signature predicting colorectal cancer relapse reveals LEMD1 promoting CRC cells migration by RhoA\/ROCK1 signaling pathway. Front Oncol. 2022;12:823696. https:\/\/doi.org\/10.3389\/fonc.2022.823696.","journal-title":"Front Oncol"},{"issue":"3","key":"1435_CR50","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bbrc.2017.02.081","volume":"485","author":"R Takeda","year":"2017","unstructured":"Takeda R, Hirohashi Y, Shen M, et al. Identification and functional analysis of variants of a cancer\/testis antigen LEMD1 in colorectal cancer stem-like cells. Biochem Biophys Res Commun. 2017;485(3):651\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2017.02.081.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1435_CR51","doi-asserted-by":"publisher","first-page":"8100","DOI":"10.1080\/21655979.2021.1985259","volume":"12","author":"Z Luo","year":"2021","unstructured":"Luo Z, Hao S, Yuan J, et al. Long non-coding RNA LINC00958 promotes colorectal cancer progression by enhancing the expression of LEM domain containing 1 via microRNA miR-3064-5p. Bioengineered. 2021;12(1):8100\u201315. https:\/\/doi.org\/10.1080\/21655979.2021.1985259.","journal-title":"Bioengineered"},{"key":"1435_CR52","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.2147\/OTT.S198126","volume":"12","author":"C Wei","year":"2019","unstructured":"Wei C, Yang C, Wang S, et al. M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22\/PI3K\/AKT signaling. Onco Targets Ther. 2019;12:3051\u201363. https:\/\/doi.org\/10.2147\/OTT.S198126.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"1435_CR53","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12703","volume":"21","author":"M Xu","year":"2021","unstructured":"Xu M, Lin B, Zheng D, et al. LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt\/\u03b2-catenin signaling pathway and epithelial-mesenchymal transition. Oncol Lett. 2021;21(6):442. https:\/\/doi.org\/10.3892\/ol.2021.12703.","journal-title":"Oncol Lett"},{"issue":"1","key":"1435_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/bjc.2016.167","volume":"115","author":"T Sasahira","year":"2016","unstructured":"Sasahira T, Kurihara M, Nakashima C, Kirita T, Kuniyasu H. LEM domain containing 1 promotes oral squamous cell carcinoma invasion and endothelial transmigration. Br J Cancer. 2016;115(1):52\u20138. https:\/\/doi.org\/10.1038\/bjc.2016.167.","journal-title":"Br J Cancer"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01435-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01435-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01435-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:25:27Z","timestamp":1786944327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01435-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01435-8","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest concerning the publishing of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human tissue samples was approved by the Ethics Committee of The Second Hospital of Tianjin Medical University (Approval No. KY2023K207). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"125"}}